<DOC>
	<DOCNO>NCT00055887</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Drugs efaproxiral may make tumor cell sensitive radiation therapy . It yet know chemotherapy combine radiation therapy effective without efaproxiral treat non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy combine radiation therapy without efaproxiral treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy With Without Efaproxiral Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient stage IIIA IIIB non-small cell lung cancer treat induction chemotherapy follow radiotherapy without efaproxiral . - Compare time progression , response rate , pattern failure patient treat regimen . - Determine safety efaproxiral patient . - Determine pharmacokinetics efaproxiral patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord chemotherapy regimen , Karnofsky performance status ( 70-80 % vs 90-100 % ) , disease stage ( IIIA v IIIB ) . - Induction therapy phase : Patients receive 1 follow induction chemotherapy regimen : - Paclitaxel carboplatin : Patients receive paclitaxel IV carboplatin IV day 1 . Treatment repeat every 21 day total 2 course . - Cisplatin gemcitabine : Patients receive cisplatin IV day 2 gemcitabine IV day 1 , 8 , 15 . Treatment repeat every 28 day total 2 course . - Cisplatin vinorelbine : Patients receive cisplatin IV day 1 vinorelbine IV day 1 , 8 , either 15 22 . Treatment repeat every 28 day total 2 course . - Randomized phase : Within 42 day completion chemotherapy , patient randomize 1 2 treatment arm . - Arm I : Patients receive efaproxiral IV 30-45 minute supplemental oxygen undergo concurrent radiotherapy 5 day week 7 week . - Arm II : Patients receive supplemental oxygen undergo radiotherapy arm I . Quality life assess baseline , day 1 16 radiotherapy , monthly 3 month , every 3 month 2 year , every 6 month 3 year , annually thereafter . Patients follow monthly 3 month , every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 659 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Efaproxiral</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advance , unresectable nonsmall cell lung cancer 1 follow subtypes : Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Poorly differentiate carcinoma Stage IIIA IIIB T1 T2 , N2 T3 , N1 N2 T4 , N Any T , N3 Histological cytological confirmation least 1 positive lymph node require large mediastinal node basis stage III disease le 2.0 cm diameter Clinically radiologically measurable disease least 2.0 cm Partially resect stage IIIB disease allow provide measurable lesion remain No pleural effusion bloody , cytologically positive , reaccumulated thoracentesis No metastatic disease CT scan MRI PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Hemoglobin least 10 g/dL WBC least 3,000/mm^3 Absolute granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal Creatinine great 1.5 mg/dL Cardiovascular No clinically active congestive heart failure No unstable angina No severe arrhythmia ECG Pulmonary FVC FEV_1 least 50 % normal Resting oxygen saturation pulse oximetry ( SpO_2 ) least 90 % room air Exercise SpO_2 least 90 % room air Other Not pregnant nursing Negative pregnancy test Fertile female patient must use effective contraception 30 day study therapy Male patient must use effective contraception 90 day study therapy No loss 10 % body weight within past 3 month No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No significantly alter mental status dementia would preclude give informed consent No active infection No serious underlie medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy More 28 day since prior biologic therapy No concurrent colonystimulating factor ( randomized phase ) No biologic therapy 1 month study therapy No immune response modifier 1 month study therapy Chemotherapy No prior systemic chemotherapy Endocrine therapy No hormonal therapy 1 month study therapy Radiotherapy No prior thoracic radiotherapy Surgery See Disease Characteristics No prior total surgical resection Other More 28 day since prior investigational drug device No prior efaproxiral No cytotoxic therapy 1 month study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
</DOC>